Lupus is an autoimmune disease, chronic in nature. This disease causes the immune system of the patient’s body to attack its own cells and tissues. The manufacturers and players in the global lupus therapeutics market offer treatment therapeutics for various types of lupus disorders, including SLE or systemic lupus erythematosus, drug induced lupus erythematosus, neonatal lupus, and cutaneous lupus erythematosus. The treatment solutions offered by the players in the global lupus therapeutics market include immunosuppressive drugs, antihypertensive drugs, immunosuppressive drugs, and biologic drugs, among others. Based on diagnosis, the classifications in the global lupus therapeutics market include biopsy, laboratory tests, and imaging tests, among others. These solutions in the global lupus therapeutics market are distributed through various channels, most significantly including online pharmacies, retail pharmacies, and hospital pharmacies, among others.
The rising prevalence of lupus disorders across the world is one of the most prominent driving factors, influencing the growth in the global lupus therapeutics market. Furthermore, the rising amount of investments, aimed at developing high end and technologically enabled healthcare infrastructure and facilities in various developed as well as developing economies is also expected to foster the growth and development within the global lupus therapeutics market in coming years. The increasing number of research and drug development as well as drug discovery projects under taken by the industry players are also affecting the growth in the global lupus therapeutics market. However, the risk of adverse side effects caused by the medications and therapeutics in the global lupus therapeutics market may restrict the industry’s growth in near future.
The major incumbent participants and stakeholders working in the global lupus therapeutics market include Zydus Cadila, Glenmark Pharmaceuticals, Ltd., Dr. Reddy’s Laboratories, Ltd., Johnson & Johnson Private Limited, Eli Lilly and Company, Abbott Laboratories, Mylan N. V.m Sanofi, Sun Pharmaceutical Industries Ltd., Lupin, Merck & Co., Inc., Pfizer Inc., LEO Pharma A/S, Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, AstraZeneca, Bausch Health Companies, Inc., AbbVie, Inc., F Hoffmann La Roche, Ltd., Teva Pharmaceutical Industries, Ltd., GlaxoSmithKline PLC, and Sumitomo Corporation, among others. Manufacturers and players working in the global lupus therapeutics market are focusing on gaining regulatory approvals for their new drug products.
Geographically, the regional market of North America leads the global lupus therapeutics market in terms of demand and industry share. This trend can be attributed to the presence of high number of leading industry players as well as the presence of highly sophisticated and well-trenched medical and healthcare infrastructure in the region.